Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06348238 · ClinicalTrials.gov registry record · NA

Strategies to Improve Well-Being and Diabetes Management

A NA study of Diabetes Mellitus, Type 2, sponsored by Elizabeth Scharnetzki.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
1
Study location

NCT06348238: Recruiting NA study of Diabetes Mellitus, Type 2, sponsored by Elizabeth Scharnetzki.

NCT06348238 is a NA study of Diabetes Mellitus, Type 2 that is actively recruiting participants, run by Elizabeth Scharnetzki. The registered enrollment target is 150 participants, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06348238, a NA study of Diabetes Mellitus, Type 2, is actively recruiting participants, sponsored by Elizabeth Scharnetzki.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

This project aims to implement an adapted self-affirmation intervention among a population of individuals with diabetes to reduce the negative psychosocial impacts of stigma. In a self-affirmation, participants are guiding through a writing exercise writing designed to reinforce sources of self-worth before they encounter or engage in stressful or stigmatizing events. Participants in this study will be asked to complete self-affirmation exercises before their 3-month wellness appointments with their endocrinologists over the course of a year. The main questions the investigators are asking are: * Will self-affirmation reduce feelings of stigmatization? * Will self-affirmation increase self-efficacy and motivation to engage in condition management behaviors. * Will self-affirmation improve blood glucose control. Participants will be randomly assigned to either the intervention condition or a waitlist control condition. Participants in the waitlist control condition will also complete writing exercises but they will be abbreviated (this in the psychological literature is referred to as a "low affirmation condition"). At the end of the study, waitlist control participants will have access to the full exercise should they like to receive it. After each appointment and self-affirmation, participants will complete surveys assessing feelings of stigma and motivation to engage in condition management. All participants will already be using continuous glucose monitors. The investigators will compare both survey responses and continuous glucose data between our conditions to assess the efficacy of the self-affirmation intervention.

Primary Outcome

Used to assess participants' concerns about experiencing diabetes-specific stigma-induced identity threat while receiving care for T2D. A 1 (Strongly disagree) to 7 (Strongly agree) Likert response scale is used for all items. A composite score is created by summing all items. Higher values indicate greater social identity threat concerns.

Conditions Studied

Interventions

  • BEHAVIORAL Self-Affirmation

Study Locations (1)

Maine

  • MaineHealth Institute for Research, Center for Interdisciplinary and Population Health Research - Westbrook

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2024-07-24
Est. Completion 2027-02-28
Phase NA
Elizabeth Scharnetzki

1 total trials

What NCT06348238 shows while recruiting

NCT06348238 is an interventional study that assigns participants to a tested intervention. The registered 150 participants enrollment target is mid-sized for trials with a published cap, below the 4,485-participant average among 348 other Diabetes Mellitus, Type 2 trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Diabetes Mellitus, Type 2 appearing as the primary indexed condition, and to 1 intervention - of which Self-Affirmation is the first listed.

NCT06348238 reports a single indexed study location in Maine.

Frequently Asked Questions

What is clinical trial NCT06348238 about?

NCT06348238 is a clinical study titled "Strategies to Improve Well-Being and Diabetes Management". This project aims to implement an adapted self-affirmation intervention among a population of individuals with diabetes to reduce the negative psychosocial impacts of stigma. In a self-affirmation, participants are guiding through a writing exercise writing designed to reinforce sources of self-wort...

What is the current status of trial NCT06348238?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2024-07-24. Estimated completion is 2027-02-28.

What conditions does trial NCT06348238 study?

This clinical trial studies the following conditions: Diabetes Mellitus, Type 2.

What interventions are being tested in trial NCT06348238?

The interventions under investigation include: Self-Affirmation (BEHAVIORAL).

Who is sponsoring clinical trial NCT06348238?

This trial is sponsored by Elizabeth Scharnetzki, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06348238 being conducted?

This trial has 1 study location across Maine. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes Mellitus, Type 2

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06348238's enrollment target sits among peer trials

150 173rd of 348 higher than 173 of 348 other Diabetes Mellitus, Type 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes Mellitus, Type 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00412594 · 150 participants · Phase 2

    Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia

  • NCT01484730 · 150 participants

    A Pilot Study to Evaluate Multi-Spectral and Laser Speckle Imaging and Multiphoton Microscopy During Vascular Occlusion

  • NCT01985919 · 150 participants

    Protocol for Facilitating the Acquisition of Research Bone Marrow and Blood Samples

  • NCT02016248 · 150 participants · NA

    SBRT Boost for Unfavorable Prostate Cancer'

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06348238, the US trial registry maintained by the National Library of Medicine. NCT06348238 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.